BiotechTube

LY517717 + enoxaparin

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Total Knee Replacement

Conditions

Total Knee Replacement, Total Hip Replacement

Trial Timeline

Dec 1, 2003 → May 1, 2005

NCT ID
NCT00074828

About LY517717 + enoxaparin

LY517717 + enoxaparin is a phase 2 stage product being developed by Eli Lilly for Total Knee Replacement. The current trial status is completed. This product is registered under clinical trial identifier NCT00074828. Target conditions include Total Knee Replacement, Total Hip Replacement.

What happened to similar drugs?

3 of 5 similar drugs in Total Knee Replacement were approved

Approved (3) Terminated (1) Active (2)
✅placebo + aspirin + clopidogrel + aspirin OR prasugrel + aspirinDaiichi SankyoApproved
✅Clopidogrel + TicagrelorAstraZenecaApproved
✅Zoledronic acid 5mgNovartisApproved
🔄Exacyl®BayerPhase 3
🔄etoricoxib (MK0663) 120 mg + Comparator: Placebo + etoricoxib (MK0663) 90 mgOrganonPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00074828Phase 2Completed

Competing Products

11 competing products in Total Knee Replacement

See all competitors
ProductCompanyStageHype Score
placebo + aspirin + clopidogrel + aspirin OR prasugrel + aspirinDaiichi SankyoApproved
43
Glucagon receptor antagonist LY2409021 + PlaceboEli LillyPre-clinical
22
Clopidogrel + TicagrelorAstraZenecaApproved
43
Zoledronic acid 5mgNovartisApproved
35
LNA043 + PlaceboNovartisPhase 1
29
DenosumabAmgenPhase 2
35
48-hour ropivacaine infusions + Single dose ropivacaine + Patient controlled analgesicsSanofiPre-clinical
26
Exacyl®BayerPhase 3
37
Enoxaparin + Apixaban + BAY1213790BayerPhase 2
32
etoricoxib (MK0663) 120 mg + Comparator: Placebo + etoricoxib (MK0663) 90 mgOrganonPhase 3
34
CeftobiproleBasilea PharmaceuticaPhase 1
23